Dr. Aude Chapuis is an expert in hematopoietic stem cell transplantation and in developing novel ways to help a patient’s immune system target life-threatening viral infections and various malignancies. Building on positive results with adoptive transfer of T cells targeting specific antigens in HIV and melanoma, her Program in Immunology laboratory is focused on understanding the factors associated with successful therapies so that adoptive T cells therapies can be further optimized to better eliminate tumors.
With particular expertise in obtaining and validating T cell receptors (TCRs) that bind specific target antigens, generating antigen-specific T cells and preparing certified T cell products for patients, ongoing studies in the Chapuis lab aim to 1) improve the survival and intrinsic antitumor activity of adoptively transferred T cells and 2) modulate the immune “microenvironment” in the patient to improve therapeutic T cell activity. Clinical trials and correlative laboratory studies are underway for patients with myeloid leukemia, lung cancer and Merkel cell carcinoma.
Paulson KG, Park SY, Vandeven NA, Lachance K, Thomas H, Chapuis AG, Harms KL, Thompson JA, Bhatia S, Stang A, Nghiem P. Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics.
Oda SK, Daman AW, Garcia NM, Wagener F, Schmitt TM, Tan X, Chapuis AG, Greenberg PD. A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia.
Chapuis AG, Desmarais C, Emerson R, Schmitt TM, Shibuya K, Lai I, Wagener F, Chou J, Roberts IM, Coffey DG, Warren E, Robbins H, Greenberg PD, Yee C. Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8+ T Cells In Vivo.